Search Our Publications and Tools
-
SUMMARY REPORT: Optimal Prescribing and Use of Blood Glucose Test Strips for Self-Monitoring of Blood Glucose
December 8, 2009
The Canadian Agency for Drugs and Technologies in Health (CADTH) ― through its Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) — has released a series of Optimal Therapy Reports on the self-monitoring of blood glucose (SMBG), together with recommendations and int...
-
Gap Analysis and Key Messages for the Prescribing and Use of Blood Glucose Test Strips for the Self-Monitoring of Blood Glucose
November 12, 2009
-
COMPUS Diabetes Project — Optimal Self-Monitoring of Blood Glucose: PROJECT IN BRIEF
November 12, 2009
-
Optimal Therapy Recommendations for the Prescribing and Use of Blood Glucose Test Strips
July 28, 2009
-
Second-Line Therapy for Patients with Diabetes Inadequately Controlled on Metformin — PROJECT PROTOCOL
July 28, 2009
-
Cost-Effectiveness of Blood Glucose Test Strips in the Management of Adult Patients with Diabetes Mellitus
May 15, 2009
-
Systematic Review of Use of Blood Glucose Test Strips for the Management of Diabetes Mellitus
May 15, 2009
-
SUMMARY REPORT: Optimal Prescribing and Use of Insulin Analogues
March 31, 2009
-
Academic Detailing Upskilling Document – Insulin Analogues
March 31, 2009
-
Didactic Presentation for Pharmacists
March 31, 2009
-
Interactive Case Studies
March 31, 2009
-
Current Practice Analysis of Health Care Providers and Patients on Self- Monitoring of Blood Glucose
March 27, 2009
-
Current Utilization of Blood Glucose Test Strips in Canada
March 9, 2009
-
INSULIN MANAGEMENT: Evidence, Tips & Pearls
March 9, 2009
-
Gap Analysis and Key Messages for the Prescribing and Use of Insulin Analogues
January 20, 2009
This report is prepared by the Canadian Optimal Medication Prescribing and Utilization Service (COMPUS), a service of the Canadian Agency for Drugs and Technologies in Health (CADTH). This report is based on the comparison of evidence-based recommendations related to the prescribing and use of insul...
-
Optimal Therapy Recommendations for the Prescribing and Use of Insulin Analogues
January 20, 2009
This report is based on comprehensive meta-analyses — Long-Acting Insulin Analogues for the Treatment of Diabetes Mellitus: Meta-analyses of Clinical Outcomes, Update of CADTH Technology Report No. 92; and Rapid-Acting Insulin Analogues for the Treatment of Diabetes Mellitus: Meta-analyses of ...
-
Use of Blood Glucose Test Strips for the Management of Diabetes Mellitus – PROJECT PROTOCOL
October 15, 2008
This report has been prepared by the Canadian Optimal Medication Prescribing and Utilization Service (COMPUS), a service of the Canadian Agency for Drugs and Technologies in Health (CADTH). It contains a comprehensive review of existing public literature, studies, materials, and other information an...
-
Evaluation Framework
May 15, 2008
The Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) is producing a collection of intervention tools to disseminate its key messages on proton pump inhibitors (PPIs). The following tools are being developed in collaboration with experts in continuing professional development...
-
Alternative Prescription Pad
April 15, 2008
-
Long-acting insulin analogues for the treatment of diabetes mellitus:
March 25, 2008
Most studies of the long-acting insulin analogues were of poor quality and were not designed to measure differences in clinically important outcomes. There is no evidence that IGlar offers benefit over NPH insulin in children with type 1 DM, although IDet may have benefits in terms of reduced noc...
-
An economic evaluation of insulin analogues for the treatment
March 25, 2008
The objective of this economic assessment was to determine the cost-effectiveness of using IAs in the management of T1DM and T2DM, compared to HIs, in Canada. The results of this analysis may assist those who are responsible for making informed judgments on the reimbursement and prescribing of IAs f...
-
Current utilization of insulin products in Canada
March 1, 2008
To identify and promote the implementation of evidence-based and cost-effective optimal therapy in the prescribing and use of long and rapid-acting insulin analogues, COMPUS followed the process outlined in the flow chart to the right. This report represents Current Utilization Analysis step....
-
Rapid-acting insulin analogues for the treatment of diabetes mellitus: meta-analyses of clinical outcomes
January 15, 2008
The bulk of the available evidence on rapid-acting insulin analogues for both type 1 and type 2 diabetes consists of short- to medium-term comparisons with HI in terms of A1c and hypoglycemia. Most studies were of poor methodological quality. Based on the available evidence, the benefit of rapid...
-
GRADE evidence profiles on long and rapid acting insulin analogues for the treatment of diabetes mellitus
January 15, 2008
The Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) has applied the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to its work. The GRADE approach was developed to assist recommendation-making groups in making judgments about the qualit...
-
Current practice analysis: insulin analogues. A qualitative analysis of Canadian physician perceptions and use of insulin analogues
January 1, 2008
For less than a decade, insulin analogues have been available to be used in combination with, or as replacements for, human insulins, providing new treatment options with type 1 or type 2 diabetes. Several recent reviews of randomized controlled trials comparing regular human and analogue insuli...
-
Physician Self-Audit Tool
September 1, 2007
The Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) self-audit tool is intended as a template and may be customized to suit the requirements of the distributor (provincial jurisdictions or continuing education providers, for example). The information collected enables the di...
-
Upskilling Document
April 15, 2007
The academic detailing upskilling document on proton pump inhibitors is intended as a companion document to the Canadian Agency for Drugs and Technologies in Health’s (CADTH’s) Scientific Report entitled, Evidence for PPI Use in Gastroesophageal Reflux Disease, Dyspepsia and Peptic Ul...
-
Academic Detailing Newsletter
April 15, 2007
Optimal Therapy Newsletter: Proton Pump Inhibitors...
-
COMPUS/RxFiles Pearls Document
April 15, 2007
OBJECTIVE COMPARATIVE DRUG INFORMATION & EDUCATION RxFiles Academic Detailing Program Saskatchewan’s Academic Detailing Program...
-
Economic models and conclusions for the treatment of dyspepsia; and gastroesophageal reflux disease – related heartburn and the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal complications.
April 1, 2007
The clinical and economic evidence for the treatment of common GI ailments (i.e., uninvestigated GERD, uninvestigated dyspepsia, and NSAID ulcer = prophylaxis) in the general practice setting suggests that PPIs (at a price equal to or less than $1.25 per day) may be cost-effective depending on thewi...
-
Presentation for Pharmacists - Proton Pump Inhibitors and the Treatment
April 1, 2007
Presentation for Pharmacists...
-
Quick Reference Prescribing Aid
April 1, 2007
-
Proton Pump Inhibitor Project Overview: Executive Summary
March 15, 2007
This Executive Summary is based on a comprehensive Scientific Report (Optimal Therapy Report – COMPUS: Evidence for PPI use in gastroesophageal reflux disease, dyspepsia and peptic ulcer disease: scientific report) and economic report on the topic, prepared by the Canadian Optimal Medicatio...
-
Evidence for PPI use in gastroesophageal reflux disease, dyspepsia and peptic ulcer disease: scientific report
March 15, 2007
1. ISSUE The Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) was tasked by the federal, provincial, and territorial ministries of health to identify and promote the implementation of evidence-based and cost-effective optimal therapy in the prescribing and use of proton ...
-
Current practice analysis report for the prescribing and use of proton pump inhibitors
March 15, 2007
The purpose of this report is to foster an understanding of how proton pump inhibitors (PPIs) are being prescribed and used in Canada. It is critical to have a clear picture of the current practice in Canada regarding PPIs so that gaps between the current practice and the optimal prescribing and use...
-
Project in Brief - The COMPUS PPI Project – From Evidence to Interventions to Improved Health Outcomes
March 15, 2007
Key Messages All PPIs are equally efficacious in the initial treatment of GERD, dyspepsia and other common GI conditions. Doubling the standard daily doses of PPIs, as initial therapy, is no better than standard daily dose therapy. PPIs are not efficacious in treating cough, asthma or laryngeal...
-
Interventions for appropriate prescribing of proton pump inhibitors: a literature review
March 1, 2007
The studies in the review suggest that combining educational multifaceted interventions that involve both professionals and patients with policy intervention may encourage appropriate prescribing and use of proton pump inhibitors. However, the decision on the selection of interventions should be tai...
-
Gap analysis report for the prescribing and use of proton pump inhibitors
March 1, 2007
The purpose of this report is to identify gaps in the current prescribing and use of PPIs. This document presents three gaps in the use of PPIs as determined by a review of current practice in the prescribing and use of PPIs in Canada compared with the Evidence Statements contained in theScienti...
-
Selection of interventions report: PPI project
March 1, 2007
The intent of this report is to identify a variety of interventions that would be best suited to optimizing the prescribing and use of proton pump inhibitors in different settings. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and ...
-
Proton Pump Inhibitor Project Overview: Summaries
March 1, 2007
This Executive Summary is based on a comprehensive Scientific Report (Optimal Therapy Report – COMPUS: Evidence for PPI use in gastroesophageal reflux disease, dyspepsia and peptic ulcer disease [Scientific Report]) and economic report on the topic, prepared by the Canadian Optimal Medication ...
-
Didactic Presentation for Pharmacists
February 1, 2007
-
Didactic Presentation for Physicians
February 1, 2007
-
Interactive Presentation for Physicians
February 1, 2007